Oral Anticoagulant Therapy

Whitlon, 1978, Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition, Biochemistry, 17, 1371, 10.1021/bi00601a003 Fasco, 1982, Evidence that warfarin anticoagulant action involves two distinct reductase activities, J Biol Chem, 257, 11210, 10.1016/S0021-9258(18)33742-6 Choonara, 1988, The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin, Br J Clin Pharmacol, 25, 1, 10.1111/j.1365-2125.1988.tb03274.x Trivedi, 1988, Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3-epoxide: evidence for multiple pathways of hydroxyvitamin K formation, Arch Biochem Biophys, 264, 67, 10.1016/0003-9861(88)90571-1 Stenflo, 1974, Vitamin K dependent modifications of glutamic acid residues in prothrombin, Proc Natl Acad Sci U S A, 71, 2730, 10.1073/pnas.71.7.2730 Nelsestuen, 1974, The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin, J Biol Chem, 249, 6347, 10.1016/S0021-9258(19)42259-X Stafford, 2005, The vitamin K cycle, J Thromb Haemost, 3, 1873, 10.1111/j.1538-7836.2005.01419.x Ansell, 2008, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 160S, 10.1378/chest.08-0670 Friedman, 1977, A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients, Biochim Biophys Acta, 494, 271, 10.1016/0005-2795(77)90155-6 Malhotra, 1985, The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins, J Biol Chem, 260, 279, 10.1016/S0021-9258(18)89728-9 Nelsestuen, 1976, Role of gamma-carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid, J Biol Chem, 251, 5648, 10.1016/S0021-9258(17)33107-1 Prendergast, 1977, Differentiation of metal ion-induced transitions of prothrombin fragment 1, J Biol Chem, 252, 840, 10.1016/S0021-9258(19)75174-6 Borowski, 1986, Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. Conformation-specific antibodies directed against the phospholipid-binding site on prothrombin, J Biol Chem, 261, 14969, 10.1016/S0021-9258(18)66814-0 Becker, 2005, The importance of factor Xa regulatory pathways in vascular thromboresistance: focus on protein Z, J Thromb Thrombolysis, 19, 135, 10.1007/s11239-005-2473-4 Breckenridge, 1978, Oral anticoagulant drugs: pharmacokinetic aspects, Semin Hematol, 15, 19 O'Reilly, 1976, Vitamin K and the oral anticoagulant drugs, Annu Rev Med, 27, 245, 10.1146/annurev.me.27.020176.001333 Kelly, 1979, Clinical pharmacokinetics of oral anticoagulants, Clin Pharmacokinet, 4, 1, 10.2165/00003088-197904010-00001 1986 Miners, 1998, Cytochrome P4502C9: an enzyme of major importance in human drug metabolism, Br J Clin Pharmacol, 45, 525, 10.1046/j.1365-2125.1998.00721.x Godbillon, 1981, Pharmacokinetics of the enantiomers of acenocoumarol in man, Br J Clin Pharmacol, 12, 621, 10.1111/j.1365-2125.1981.tb01280.x Haustein, 1999, Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon, Semin Thromb Hemost, 25, 5, 10.1055/s-2007-996417 Mentré, 1998, Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients, Clin Pharmacol Ther, 63, 64, 10.1016/S0009-9236(98)90122-9 Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee Scordo, 2002, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance, Clin Pharmacol Ther, 72, 702, 10.1067/mcp.2002.129321 Wittkowsky, 2003, Pharmacology of warfarin and related anticoagulants, Vol. 1, 15 Loebstein, 2001, Individual variability in sensitivity to warfarin: nature or nurture, Clin Pharmacol Ther, 70, 159, 10.1067/mcp.2001.117444 Lindh, 2009, Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis, Eur J Clin Pharmacol, 65, 365, 10.1007/s00228-008-0584-5 Aithal, 1999, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet, 353, 717, 10.1016/S0140-6736(98)04474-2 Higashi, 2002, Influence of CYP2C9 genetic variants on the risk of over anticoagulation and of bleeding events during warfarin therapy, JAMA, 287, 1690, 10.1001/jama.287.13.1690 Veenstra, 2005, CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes, Clin Pharmacol Ther, 77, 353, 10.1016/j.clpt.2005.01.019 Chern, 2006, CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese, Clin Chim Acta, 367, 108, 10.1016/j.cca.2005.11.026 Herman, 2006, A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy, Thromb Haemost, 95, 192, 10.1055/s-0037-1612583 Visser, 2004, The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon, Thromb Haemost, 92, 61, 10.1160/TH03-12-0741 Takahashi, 2004, CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences, Clin Pharmacol Ther, 75, 376, 10.1016/j.clpt.2004.01.007 Beinema, 2008, Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon, Thromb Haemost, 100, 1052 Zimmermann, 1974, Biochemical basis of hereditary resistance to warfarin in the rat, Biochem Pharmacol, 23, 1033, 10.1016/0006-2952(74)90002-1 Rost, 2004, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, 427, 537, 10.1038/nature02214 Li, 2004, Identification of the gene for vitamin K epoxide reductase, Nature, 427, 541, 10.1038/nature02254 D'Andrea, 2005, A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin, Blood, 105, 645, 10.1182/blood-2004-06-2111 Rieder, 2005, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N Engl J Med, 352, 2285, 10.1056/NEJMoa044503 Geisen, 2005, VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation, Thromb Haemost, 94, 773, 10.1160/TH05-04-0290 Sconce, 2005, The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen, Blood, 106, 2329, 10.1182/blood-2005-03-1108 Harrington, 2005, Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1, Thromb Haemost, 93, 23, 10.1160/TH04-08-0540 Anthony, 2009, Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium, Clin Pharmacol Ther, 86, 425, 10.1038/clpt.2009.95 Marsh, 2006, Population variation in VKORC1 haplotype structure, J Thromb Haemost, 4, 473, 10.1111/j.1538-7836.2006.01759.x Quteineh, 2005, Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose, Thromb Haemost, 94, 690, 10.1160/TH05-03-0690 2007 Holbrook, 2005, Systematic overview of warfarin and its drug and food interactions, Arch Intern Med, 165, 1095, 10.1001/archinte.165.10.1095 Orme, 1976, Enantiomers of warfarin and phenobarbital, N Engl J Med, 295, 1482, 10.1056/NEJM197612232952613 Breckenridge, 1974, Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man, Clin Pharmacol Ther, 15, 424, 10.1002/cpt1974154424 O'Reilly, 1974, Studies on the optical enantiomorphs of warfarin in man, Clin Pharmacol Ther, 16, 348, 10.1002/cpt1974162348 O'Reilly, 1980, Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man, J Clin Invest, 65, 746, 10.1172/JCI109722 Toon, 1986, The warfarin-sulfinpyrazone interaction: stereochemical considerations, Clin Pharmacol Ther, 39, 15, 10.1038/clpt.1986.3 O'Reilly, 1976, The stereoselective interaction of warfarin and metronidazole in man, N Engl J Med, 295, 354, 10.1056/NEJM197608122950702 O'Reilly, 1980, Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man, N Engl J Med, 302, 33, 10.1056/NEJM198001033020106 Lewis, 1974, Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone, J Clin Invest, 53, 1607, 10.1172/JCI107711 O'Reilly, 1987, Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans, Clin Pharmacol Ther, 42, 290, 10.1038/clpt.1987.149 Cropp, 1997, A review of enzyme induction of warfarin metabolism with recommendations for patient management, Pharmacotherapy, 17, 917 Ng, 2006, Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review, Am J Geriatr Pharmacother, 4, 75, 10.1016/j.amjopharm.2006.03.001 O'Reilly, 1981, Lack of effect of fortified wine ingested during fasting and anticoagulant therapy, Arch Intern Med, 141, 458, 10.1001/archinte.1981.00340040054017 Bechtold, 1984, Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins, Thromb Haemost, 51, 358, 10.1055/s-0038-1661101 Weitekamp, 1983, Prolonged bleeding times and bleeding diathesis associated with moxalactam administration, JAMA, 249, 69, 10.1001/jama.1983.03330250049027 Owens, 1962, Effect of sodium dextrothyroxine in patients receiving anticoagulants, N Engl J Med, 266, 76, 10.1056/NEJM196201112660205 O'Reilly, 1972, Studies on the interaction of warfarin and clofibrate in man, Thromb Diath Haemorrh, 27, 309 Rothschild, 1979, Hematologic perturbations associated with salicylate, Clin Pharmacol Ther, 26, 145, 10.1002/cpt1979262145 Hylek, 1998, Acetaminophen and other risk factors for excessive warfarin anticoagulation, JAMA, 279, 657, 10.1001/jama.279.9.657 Bell, 1998, Acetaminophen and warfarin: undesirable synergy, JAMA, 279, 702, 10.1001/jama.279.9.702 Mahé, 2006, Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study, Haematologica, 91, 1621 Thijssen, 2004, Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle, Thromb Haemost, 92, 797 Hylek, 2004, Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycle, Thromb Haemost, 92, 672 Weibert, 1989, Effect of erythromycin in patients receiving long-term warfarin therapy, Clin Pharm, 8, 210 Lorentz, 1985, Potentiation of warfarin anticoagulation by topical testosterone ointment, Clin Pharmacol Ther, 4, 332 Udall, 1965, Human sources and absorption of vitamin K in relation to anticoagulation stability, JAMA, 194, 127, 10.1001/jama.1965.03090150019004 Dale, 1980, Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement, Am Heart J, 99, 746, 10.1016/0002-8703(80)90625-0 Schulman, 1989, Interaction of ibuprofen and warfarin on primary haemostasis, Br J Rheumatol, 28, 46, 10.1093/rheumatology/28.1.46 Battistella, 2005, Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors, Arch Intern Med, 165, 189, 10.1001/archinte.165.2.189 Cazenave, 1973, Effects of penicillin G on platelet aggregation, release, and adherence to collagen, Proc Soc Exp Biol Med, 142, 159, 10.3181/00379727-142-36980 Brown, 1974, The hemostatic defect produced by carbenicillin, N Engl J Med, 291, 265, 10.1056/NEJM197408082910601 Roth, 1975, The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein, J Clin Invest, 56, 624, 10.1172/JCI108132 Andreotti, 2006, Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients, Eur Heart J, 27, 519, 10.1093/eurheartj/ehi485 Chesebro, 1983, Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole, Am J Cardiol, 51, 1537, 10.1016/0002-9149(83)90673-2 Turpie, 1993, A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement, N Engl J Med, 329, 524, 10.1056/NEJM199308193290802 1998, Lancet, 351, 233, 10.1016/S0140-6736(97)11475-1 Schelleman, 2010, Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk, Am J Med, 123, 151, 10.1016/j.amjmed.2009.07.020 Douketis, 2007, Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin?, Am J Med, 120, 369.e9, 10.1016/j.amjmed.2006.06.008 Holbrook, 2012, Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 141, e152S, 10.1378/chest.11-2295 Wittkowsky, 2007, Dietary supplement use among anticoagulation clinic patients, J Thromb Haemost, 5, 875, 10.1111/j.1538-7836.2007.02391.x Wittkowsky, 2001, Drug interactions update: drugs, herbs, and oral anticoagulation, J Thromb Thrombolysis, 12, 67, 10.1023/A:1012742628628 Greenblatt, 2005, Interaction of warfarin with drugs, natural substances, and foods, J Clin Pharmacol, 45, 127, 10.1177/0091270004271404 Samuels, 2005, Herbal remedies and anticoagulant therapy, Thromb Haemost, 93, 3, 10.1160/TH04-05-0285 Izzo, 2005, Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction, Int J Cardiol, 98, 1, 10.1016/j.ijcard.2003.06.039 Jiang, 2005, Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects, Br J Clin Pharmacol, 59, 425, 10.1111/j.1365-2125.2005.02322.x Engelsen, 2002, Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomized, double blind, placebo-crossover trial, Thromb Haemost, 87, 1075, 10.1055/s-0037-1613135 Yuan, 2004, Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial, Ann Intern Med, 141, 23, 10.7326/0003-4819-141-1-200407060-00011 O'Reilly, 1980, “Resistance” to warfarin due to unrecognized vitamin K supplementation, N Engl J Med, 303, 160, 10.1056/NEJM198007173030317 Suttie, 1988, Vitamin K deficiency from dietary vitamin K restriction in humans, Am J Clin Nutr, 47, 475, 10.1093/ajcn/47.3.475 1996 Bovill, 1992 Booth, 1997, Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content, Thromb Haemost, 77, 504, 10.1055/s-0038-1655997 Nutescu, 2006, Warfarin and its interactions with foods, herbs and other dietary supplements, Expert Opin Drug Saf, 5, 433, 10.1517/14740338.5.3.433 Harris, 1995, Interaction of dietary factors with oral anticoagulants: review and applications, J Am Diet Assoc, 95, 580, 10.1016/S0002-8223(95)00158-1 Wittkowsky, 2008, Dietary supplements, herbs and oral anticoagulants: the nature of the evidence, J Thromb Thrombolysis, 25, 72, 10.1007/s11239-007-0110-0 Barcellona, 2002, Patient education and oral anticoagulant therapy, Haematologica, 87, 1081 Mammen, 1992, Coagulation abnormalities in liver disease, Hematol Oncol Clin North Am, 6, 1247, 10.1016/S0889-8588(18)30273-9 Deitcher, 2002, Interpretation of the international normalised ratio in patients with liver disease, Lancet, 359, 47, 10.1016/S0140-6736(02)07282-3 Richards, 1943, Influence of fever upon the action of 3,3methylene bis-(4-hydroxoycoumarin), Science, 97, 313, 10.1126/science.97.2518.313 Zevin, 1999, Drug interactions with tobacco smoking. An update, Clin Pharmacokinet, 36, 425, 10.2165/00003088-199936060-00004 Evans, 2005, Increase in international normalized ratio after smoking cessation in a patient receiving warfarin, Pharmacotherapy, 25, 1656, 10.1592/phco.2005.25.11.1656 Kuykendall, 2004, Possible warfarin failure due to interaction with smokeless tobacco, Ann Pharmacother, 38, 595, 10.1345/aph.1D087 Self, 2006, Does heart failure exacerbation increase response to warfarin? A critical review of the literature, Curr Med Res Opin, 22, 2089, 10.1185/030079906X132479 Dreisbach, 2003, Cytochrome P4502C9 activity in end-stage renal disease, Clin Pharmacol Ther, 73, 475, 10.1016/S0009-9236(03)00015-8 Gurwitz, 1992, Aging and the anticoagulant response to warfarin therapy, Ann Intern Med, 116, 901, 10.7326/0003-4819-116-11-901 Shepherd, 1977, Age as a determinant of sensitivity to warfarin, Br J Clin Pharmacol, 4, 315, 10.1111/j.1365-2125.1977.tb00719.x Hodges, 1990, Age-related changes in the circulating levels of congeners of vitamin K2, menaquinone-7 and menaquinone-8, Clin Sci (Lond), 78, 63, 10.1042/cs0780063 Garcia, 2005, Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population, Chest, 127, 2049, 10.1378/chest.127.6.2049 Wessler, 1984, Warfarin. From bedside to bench, N Engl J Med, 311, 645, 10.1056/NEJM198409063111007 Zivelin, 1993, Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors, J Clin Invest, 92, 2131, 10.1172/JCI116814 Patel, 1996, Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma, Pediatr Res, 39, 826, 10.1203/00006450-199605000-00014 Weitz, 1990, Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors, J Clin Invest, 86, 385, 10.1172/JCI114723 Quick, 1935, The prothrombin time in haemophilia and in obstructive jaundice, J Biol Chem, 109, 73 Kirkwood, 1983, Calibration of reference thromboplastins and standardisation of the prothrombin time ratio, Thromb Haemost, 49, 238, 10.1055/s-0038-1657371 van den Besselaar, 2010, Thromboplastin standards, Biologicals, 38, 430, 10.1016/j.biologicals.2010.02.012 World Health Organization Expert Committee on Biological Standardization, 1983 Johnston, 1996, Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio, J Lab Clin Med, 128, 214, 10.1016/S0022-2143(96)90014-1 Tripodi, 2007, The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation, Hepatology, 46, 520, 10.1002/hep.21732 Bellest, 2007, A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology, Hepatology, 46, 528, 10.1002/hep.21680 Lind, 1999, Clinically significant differences in the International Normalized Ratio measured with reagents of different sensitivities. SPAF Investigators. Stroke Prevention in Atrial Fibrillation, Blood Coagul Fibrinolysis, 10, 215, 10.1097/00001721-199907000-00001 Poggio, 1989, The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents, Thromb Haemost, 62, 868, 10.1055/s-0038-1651019 D'Angelo, 1989, Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time, Am J Clin Pathol, 92, 321, 10.1093/ajcp/92.3.321 Poller, 1989, Effect of automation on prothrombin time test in NEQAS surveys, J Clin Pathol, 42, 97, 10.1136/jcp.42.1.97 Ray, 1990, The dependence of the International Sensitivity Index on the coagulometer used to perform the prothrombin time, Thromb Haemost, 63, 424, 10.1055/s-0038-1645059 van Rijn, 1989, Correction of instrument and reagent based differences in determination of the international normalised ratio (INR) for monitoring anticoagulant therapy, Clin Chem, 35, 840, 10.1093/clinchem/35.5.840 Thomson, 1990, Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers, J Clin Pathol, 43, 679, 10.1136/jcp.43.8.679 Finck, 2001, Clinical impact of interlaboratory variation in international normalized ratio determinations, Am J Health Syst Pharm, 58, 684, 10.1093/ajhp/58.8.684 Jacobson, 1999, Significant variation in the reporting of prothrombin time results despite utilization of the INR method of reporting [abstract], Circulation, 100, I-620 Fairweather, 1998, College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy, Arch Pathol Lab Med, 122, 768 Ng, 1993, Failure of the International Normalized Ratio to generate consistent results within a local medical community, Am J Clin Pathol, 99, 689, 10.1093/ajcp/99.6.689 Poller, 1987, Laboratory control of oral anticoagulants, Br Med J (Clin Res Ed), 294, 1184, 10.1136/bmj.294.6581.1184 Kazama, 1990, Evaluation of international normalized ratios by a controlled field survey with 4 different thromboplastin reagents, Thromb Haemost, 64, 535, 10.1055/s-0038-1647353 van den Besselaar, 1993, Status of present and candidate International Reference Preparations (IRP) of thromboplastin for the prothrombin time: a report of the Subcommittee for Control of Anticoagulation, Thromb Haemost, 69, 85, 10.1055/s-0038-1651553 Duncan, 1994, Effect of concentration of trisodium citrate anticoagulant on calculation of the International Normalised Ratio and the International Sensitivity Index of thromboplastin, Thromb Haemost, 72, 84, 10.1055/s-0038-1648816 Adcock, 1997, Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing, Am J Clin Pathol, 107, 105, 10.1093/ajcp/107.1.105 Harrison, 1997, Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy, Ann Intern Med, 126, 133, 10.7326/0003-4819-126-2-199701150-00006 O'Reilly, 1968, Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose, Circulation, 38, 169, 10.1161/01.CIR.38.1.169 Crowther, 1999, A randomized trial comparing 5-mg and 10-mg warfarin loading doses, Arch Intern Med, 159, 46, 10.1001/archinte.159.1.46 Kovacs, 2003, Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial, Ann Intern Med, 138, 714, 10.7326/0003-4819-138-9-200305060-00007 Siguret, 2005, Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen, Am J Med, 118, 137, 10.1016/j.amjmed.2004.07.053 O'Connell, 2000, Evaluation of warfarin initiation regimens in elderly inpatients, Pharmacotherapy, 20, 923, 10.1592/phco.20.11.923.35260 Ageno, 2001, Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement, Am J Cardiol, 88, 40, 10.1016/S0002-9149(01)01582-X Vecsler, 2006, Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin, Thromb Haemost, 95, 205, 10.1160/TH05-06-0446 Herman, 2006, The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement, Thromb Haemost, 95, 782, 10.1160/TH05-10-0678 Limdi, 2008, Influence of CYP2C9 and VKORC1on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans, Pharmacogenomics, 9, 511, 10.2217/14622416.9.5.511 Voora, 2005, Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype, Thromb Haemost, 93, 700, 10.1160/TH04-08-0542 Gage, 2008, Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin, Clin Pharmacol Ther, 84, 326, 10.1038/clpt.2008.10 Anderson, 2007, Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation, Circulation, 116, 2563, 10.1161/CIRCULATIONAHA.107.737312 Caraco, 2008, CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study, Clin Pharmacol Ther, 83, 460, 10.1038/sj.clpt.6100316 Hillman, 2005, A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data, Clin Med Res, 3, 137, 10.3121/cmr.3.3.137 Klein, 2009, Estimation of the warfarin dose with clinical and pharmacogenetic data [published correction appears in N Engl J Med 2009;361(16):1613], N Engl J Med, 360, 753 Joffe, 2004, Warfarin dosing and cytochrome P450 2C9 polymorphisms, Thromb Haemost, 91, 1123, 10.1160/TH04-02-0083 Limdi, 2009, Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy, Blood Cells Mol Dis, 43, 119, 10.1016/j.bcmd.2009.01.019 Palareti, 2005, Risks factors for highly unstable response to oral anticoagulation: a case-control study, Br J Haematol, 129, 72, 10.1111/j.1365-2141.2005.05417.x Forfar, 1982, Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio, Am Heart J, 103, 445, 10.1016/0002-8703(82)90292-7 White, 2007, Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V, Arch Intern Med, 167, 239, 10.1001/archinte.167.3.239 Cannegieter, 1995, Optimal oral anticoagulant therapy in patients with mechanical heart valves, N Engl J Med, 333, 11, 10.1056/NEJM199507063330103 Connolly, 2008, Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation, 118, 2029, 10.1161/CIRCULATIONAHA.107.750000 Petersen, 1989, Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study, Lancet, 1, 175, 10.1016/S0140-6736(89)91200-2 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, 1990, The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation, N Engl J Med, 323, 1505, 10.1056/NEJM199011293232201 Ezekowitz, 1992, Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation, N Engl J Med, 327, 1406, 10.1056/NEJM199211123272002 The European Atrial Fibrillation Trial Study Group, 1995, Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia, N Engl J Med, 333, 5, 10.1056/NEJM199507063330102 van der Meer, 1993, Bleeding complications in oral anticoagulant therapy. An analysis of risk factors, Arch Intern Med, 153, 1557, 10.1001/archinte.1993.00410130073007 Charney, 1988, Anticoagulation clinics and the monitoring of anticoagulant therapy, Int J Cardiol, 18, 197, 10.1016/0167-5273(88)90165-9 Wilson, 1991, Low-intensity anticoagulation in mechanical cardiac prosthetic valves, Chest, 100, 1553, 10.1378/chest.100.6.1553 Connolly, 1991, Canadian atrial fibrillation anticoagulation (CAFA) study, J Am Coll Cardiol, 18, 349, 10.1016/0735-1097(91)90585-W Hylek, 1996, An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation, N Engl J Med, 335, 540, 10.1056/NEJM199608223350802 Palareti, 2005, Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence, J Thromb Haemost, 3, 955, 10.1111/j.1538-7836.2005.01330.x Schmitt, 2003, Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range, J Thromb Thrombolysis, 15, 213, 10.1023/B:THRO.0000011377.78585.63 Rosendaal, 1993, A method to determine the optimal intensity of oral anticoagulant therapy, Thromb Haemost, 69, 236, 10.1055/s-0038-1651587 Meier, 2007, A comparison of anticoagulation results of patients managed with narrow vs. standard international normalized ratio target ranges, J Thromb Haemost, 5, 1332, 10.1111/j.1538-7836.2007.02561.x Gadisseur, 2002, Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon, Br J Haematol, 117, 940, 10.1046/j.1365-2141.2002.03493.x Pattacini, 1994, A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol), Thromb Haemost, 71, 188 Redwood, 1991, The association of age with dosage requirement for warfarin, Age Ageing, 20, 217, 10.1093/ageing/20.3.217 James, 1992, Factors affecting the maintenance dose of warfarin, J Clin Pathol, 45, 704, 10.1136/jcp.45.8.704 Mungall, 1992, Aging and warfarin therapy, Ann Intern Med, 117, 878, 10.7326/0003-4819-117-10-878 Pengo, 2003, A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment, Am J Clin Pathol, 120, 944, 10.1309/U7164E0XH5UERKRV Shalev, 2007, The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation, Thromb Res, 120, 201, 10.1016/j.thromres.2006.10.001 Witt, 2009, Outcomes and predictors of very stable INR control during chronic anticoagulation therapy, Blood, 114, 952, 10.1182/blood-2009-02-207928 Witt, 2010, Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users, J Thromb Haemost, 8, 744, 10.1111/j.1538-7836.2010.03756.x Shibata, 1998, Influence of physical activity on warfarin therapy, Thromb Haemost, 80, 203 Lenz, 2004, Potential interactions between exercise and drug therapy, Sports Med, 34, 293, 10.2165/00007256-200434050-00002 Sorano, 1993, Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal, Haemostasis, 23, 77 Sconce, 2005, Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation, Thromb Haemost, 93, 872, 10.1160/TH04-12-0773 Kurnik, 2004, Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. A prospective, controlled trial, Thromb Haemost, 92, 1018, 10.1160/TH04-06-0346 Schurgers, 2004, Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects, Blood, 104, 2682, 10.1182/blood-2004-04-1525 Reese, 2005, Low-dose vitamin K to augment anticoagulation control, Pharmacotherapy, 25, 1746, 10.1592/phco.2005.25.12.1746 Ford, 2007, Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios, J Thromb Thrombolysis, 24, 23, 10.1007/s11239-007-0014-z Rombouts, 2010, Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy, Br J Haematol, 149, 598, 10.1111/j.1365-2141.2010.08108.x Sconce, 2007, Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin, Blood, 109, 2419, 10.1182/blood-2006-09-049262 Rombouts, 2007, Daily vitamin K supplementation improves anticoagulant stability, J Thromb Haemost, 5, 2043, 10.1111/j.1538-7836.2007.02715.x de Assis, 2009, Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial, Circulation, 120, 1115, 10.1161/CIRCULATIONAHA.109.849208 Kimmel, 2007, The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study, Arch Intern Med, 167, 229, 10.1001/archinte.167.3.229 Orensky, 2005, Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic, Pharmacotherapy, 25, 1801, 10.1592/phco.2005.25.12.1801 Platt, 2008, Risk factors for nonadherence to warfarin: results from the IN-RANGE study, Pharmacoepidemiol Drug Saf, 17, 853, 10.1002/pds.1556 Beyth, 1998, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, Am J Med, 105, 91, 10.1016/S0002-9343(98)00198-3 Gitter, 1995, Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota, Mayo Clin Proc, 70, 725, 10.4065/70.8.725 Steffensen, 1997, Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort, J Intern Med, 242, 497, 10.1111/j.1365-2796.1997.tb00023.x Willey, 2004, Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting, Clin Ther, 26, 1149, 10.1016/S0149-2918(04)90187-7 Palareti, 1996, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), Lancet, 348, 423, 10.1016/S0140-6736(96)01109-9 Palareti, 1997, Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy), Thromb Haemost, 78, 1438, 10.1055/s-0038-1665430 Abdelhafiz, 2004, Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic, Clin Ther, 26, 1470, 10.1016/j.clinthera.2004.09.002 Veeger, 2005, Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism, Br J Haematol, 128, 513, 10.1111/j.1365-2141.2004.05348.x Cortelazzo, 1993, Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic, Thromb Haemost, 69, 316, 10.1055/s-0038-1651604 Chiquette, 1998, Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs, Arch Intern Med, 158, 1641, 10.1001/archinte.158.15.1641 Witt, 2005, Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy, Chest, 127, 1515, 10.1378/chest.127.5.1515 Matchar, 2002, Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial, Am J Med, 113, 42, 10.1016/S0002-9343(02)01131-2 Wilson, 2003, Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial, CMAJ, 169, 293 Ansell, 2007, Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM), J Thromb Thrombolysis, 23, 83, 10.1007/s11239-006-9022-7 van Walraven, 2006, Effect of study setting on anticoagulation control: a systematic review and metaregression, Chest, 129, 1155, 10.1378/chest.129.5.1155 Wilson, 1984, Computer assisted management of warfarin treatment, Br Med J (Clin Res Ed), 289, 422, 10.1136/bmj.289.6442.422 Ryan, 1989, Computer control of anticoagulant dose for therapeutic management, BMJ, 299, 1207, 10.1136/bmj.299.6709.1207 Weston Smith, 1989, Computer control of anticoagulant dose, BMJ, 299, 1529 Poller, 1993, Prospective comparative study of computer programs used for management of warfarin, J Clin Pathol, 46, 299, 10.1136/jcp.46.4.299 Ageno, 1998, A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy, Thromb Res, 91, 237, 10.1016/S0049-3848(98)00092-9 Poller, 1998, Multicentre randomized study of computerized anticoagulant dosage. European Concerted Action on Anticoagulation, Lancet, 352, 1505, 10.1016/S0140-6736(98)04147-6 Manotti, 2001, Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment), Haematologica, 86, 1060 Poller, 2008, An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage, J Thromb Haemost, 6, 935, 10.1111/j.1538-7836.2008.02959.x Jowett, 2009, The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study, J Thromb Haemost, 7, 1482, 10.1111/j.1538-7836.2009.03508.x Ageno, 2000, A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy, Thromb Haemost, 83, 849, 10.1055/s-0037-1613932 1997 Lucas, 1987, A novel whole blood capillary technic for measuring the prothrombin time, Am J Clin Pathol, 88, 442, 10.1093/ajcp/88.4.442 Yano, 1992, Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor, Thromb Res, 66, 583, 10.1016/0049-3848(92)90312-X Weibert, 1989, Evaluation of a capillary whole-blood prothrombin time measurement system, Clin Pharm, 8, 864 Rose, 1993, Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer, Arch Pathol Lab Med, 117, 611 Gosselin, 2000, A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods, Thromb Haemost, 83, 698, 10.1055/s-0037-1613895 van den Besselaar, 2000, A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin, Thromb Haemost, 84, 410 Kitchen, 1997, Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins, J Clin Pathol, 50, 951, 10.1136/jcp.50.11.951 Douketis, 1998, Accuracy of a portable International Normalization Ratio monitor in outpatients receiving long-term oral anticoagulant therapy: comparison with a laboratory reference standard using clinically relevant criteria for agreement, Thromb Res, 92, 11, 10.1016/S0049-3848(98)00098-X Cosmi, 2000, Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study, Thromb Res, 100, 279, 10.1016/S0049-3848(00)00323-6 Oral Anticoagulation Monitoring Study Group, 2001, Prothrombin measurement using a patient self-testing system, Am J Clin Pathol, 115, 280 Oral Anticoagulation Monitoring Study Group, 2001, Point-of-care prothrombin time measurement for professional and patient self-testing use. A multicenter clinical experience, Am J Clin Pathol, 115, 288, 10.1309/KM0J-G5V9-KCAG-CLEE Cachia, 1998, Accuracy and precision of the TAS analyser for near-patient INR testing by non-pathology staff in the community, J Clin Pathol, 51, 68, 10.1136/jcp.51.1.68 Murray, 2003, INRs and point of care testing, BMJ, 327, 5, 10.1136/bmj.327.7405.5 Jennings, 1991, Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation, J Clin Pathol, 44, 950, 10.1136/jcp.44.11.950 McCurdy, 1992, Accuracy and precision of a portable anticoagulation monitor in a clinical setting, Arch Intern Med, 152, 589, 10.1001/archinte.1992.00400150103019 Tripodi, 1993, Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio?, Thromb Haemost, 70, 921, 10.1055/s-0038-1649700 Plesch, 2008, Results of the performance verification of the CoaguChek XS system, Thromb Res, 123, 381, 10.1016/j.thromres.2008.04.021 Ryan, 2010, The reliability of point-of-care prothrombin time testing. A comparison of CoaguChek S and XS INR measurements with hospital laboratory monitoring, Int J Lab Hematol, 32, e26, 10.1111/j.1751-553X.2008.01120.x Plesch, 2009, Validation of the international normalized ratio (INR) in a new point-of-care system designed for home monitoring of oral anticoagulation therapy, Int J Lab Hematol, 31, 20, 10.1111/j.1751-553X.2007.00998.x Yelland, 2010, Assessing agreement between point of care and pathology laboratory results for INR: experiences from the Point of Care Testing in General Practice Trial, Pathology, 42, 155, 10.3109/00313020903494045 Tripodi, 1997, Determination of the International Sensitivity Index of a new near-patient testing device to monitor oral anticoagulant therapy—overview of the assessment of conformity to the calibration model, Thromb Haemost, 78, 855, 10.1055/s-0038-1657641 Perry, 2005, Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies, Thromb Haemost, 94, 1196 Gialamas, 2010, Point-of-care testing for patients with diabetes, hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review, Fam Pract, 27, 17, 10.1093/fampra/cmp084 Kaatz, 1995, Accuracy of laboratory and portable monitor international normalized ratio determinations. Comparison with a criterion standard, Arch Intern Med, 155, 1861, 10.1001/archinte.1995.00430170053006 Poller, 2002, European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point-of-care prothrombin time monitor systems, Br J Haematol, 116, 844, 10.1046/j.0007-1048.2002.03361.x Poller, 2003, European Concerted Action on Anticoagulation (ECAA). An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors, J Clin Pathol, 56, 114, 10.1136/jcp.56.2.114 Poller, 2003, Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods, BMJ, 327, 30, 10.1136/bmj.327.7405.30 Kitchen, 2006, Point-of-care International Normalised Ratios: UK NEQAS experience demonstrates necessity for proficiency testing of three different monitors, Thromb Haemost, 96, 590, 10.1160/TH04-01-0031 Jespersen, 2010, External quality assessment (EQA) for CoaguChek monitors, Thromb Haemost, 103, 936, 10.1160/TH09-10-0683 Ansell, 1996, Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management, Am Heart J, 132, 1095, 10.1016/S0002-8703(96)90040-X Christensen, 2004, Self-management of oral anticoagulant therapy: a review, J Thromb Thrombolysis, 18, 127, 10.1007/s11239-004-0209-5 Siebenhofer, 2004, Systematic review of studies of self-management of oral anticoagulation, Thromb Haemost, 91, 225, 10.1160/TH03-09-0598 Heneghan, 2006, Self-monitoring of oral anticoagulation: a systematic review and meta-analysis, Lancet, 367, 404, 10.1016/S0140-6736(06)68139-7 Dauphin, 2008, Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients, Arch Cardiovasc Dis, 101, 753, 10.1016/j.acvd.2008.10.007 Eitz, 2008, International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement, Ann Thorac Surg, 85, 949, 10.1016/j.athoracsur.2007.08.071 Ansell, 2005, Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation, Int J Cardiol, 99, 37, 10.1016/j.ijcard.2003.11.008 Fitzmaurice, 2005, An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation, Br J Haematol, 131, 156, 10.1111/j.1365-2141.2005.05739.x Landefeld, 1989, Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions, Am J Med, 87, 153, 10.1016/S0002-9343(89)80690-4 Fihn, 1993, Risk factors for complications of chronic anticoagulation. A multi-center study. Warfarin Optimized Outpatient Follow-up Study Group, Ann Intern Med, 118, 511, 10.7326/0003-4819-118-7-199304010-00005 Hylek, 1994, Risk factors for intracranial hemorrhage in outpatients taking warfarin, Ann Intern Med, 120, 897, 10.7326/0003-4819-120-11-199406010-00001 Hull, 1982, Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis, N Engl J Med, 307, 1676, 10.1056/NEJM198212303072704 Ridker, 2003, Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism, N Engl J Med, 348, 1425, 10.1056/NEJMoa035029 Kearon, 2003, Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism, N Engl J Med, 349, 631, 10.1056/NEJMoa035422 Turpie, 1988, Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement, Lancet, 1, 1242, 10.1016/S0140-6736(88)92070-3 Saour, 1990, Trial of different intensities of anticoagulation in patients with prosthetic heart valves, N Engl J Med, 322, 428, 10.1056/NEJM199002153220703 Altman, 1991, Comparison of two levels of anticoagulant therapy in patients with substitute heart valves, J Thorac Cardiovasc Surg, 101, 427, 10.1016/S0022-5223(19)36724-8 Hering, 2005, Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study, Chest, 127, 53, 10.1378/chest.127.1.53 Vink, 2003, The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis, J Am Coll Cardiol, 42, 2042, 10.1016/j.jacc.2003.07.029 Anand, 1999, Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis, JAMA, 282, 2058, 10.1001/jama.282.21.2058 Segal, 2000, Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs, J Gen Intern Med, 15, 56, 10.1046/j.1525-1497.2000.04329.x Hart, 1999, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis, Ann Intern Med, 131, 492, 10.7326/0003-4819-131-7-199910050-00003 1994, Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials, Arch Intern Med, 154, 1449, 10.1001/archinte.1994.00420130036007 The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group, 1997, A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin, Ann Neurol, 42, 857, 10.1002/ana.410420606 Stroke Prevention in Atrial Fibrillation III Investigators, 1996, Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial, Lancet, 348, 633, 10.1016/S0140-6736(96)03487-3 Hylek, 2003, Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N Engl J Med, 349, 1019, 10.1056/NEJMoa022913 Indredavik, 2005, Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation, J Intern Med, 258, 133, 10.1111/j.1365-2796.2005.01512.x O'Donnell, 2006, Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study, Lancet Neurol, 5, 749, 10.1016/S1474-4422(06)70536-1 Crowther, 2002, Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial, J Am Soc Nephrol, 13, 2331, 10.1097/01.ASN.0000027356.16598.99 Gulløv, 1998, Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study, Arch Intern Med, 158, 1513, 10.1001/archinte.158.14.1513 Coumadin Aspirin Reinfarction Study (CARS) Investigators, 1997, Randomised, double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction, Lancet, 350, 389, 10.1016/S0140-6736(97)01180-X Pengo, 1998, Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation, Am J Cardiol, 82, 433, 10.1016/S0002-9149(98)00357-9 Couban, 2005, Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer, J Clin Oncol, 23, 4063, 10.1200/JCO.2005.10.192 Garcia, 2006, The risk of hemorrhage among patients with warfarin-associated coagulopathy, J Am Coll Cardiol, 47, 804, 10.1016/j.jacc.2005.09.058 Clark, 2008, Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study, Pharmacotherapy, 28, 960, 10.1592/phco.28.8.960 Dentali, 2009, Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio, J Thorac Cardiovasc Surg, 137, 91, 10.1016/j.jtcvs.2008.06.030 Garcia, 2008, Risk of thromboembolism with short-term interruption of warfarin therapy, Arch Intern Med, 168, 63, 10.1001/archinternmed.2007.23 Delate, 2007, Falsely elevated international normalized ratio values in patients undergoing anticoagulation therapy: a descriptive evaluation, Chest, 131, 816, 10.1378/chest.06-2200 Coon, 1974, Hemorrhagic complications of anticoagulant therapy, Arch Intern Med, 133, 386, 10.1001/archinte.1974.00320150060006 Jaffin, 1987, Significance of occult gastrointestinal bleeding during anticoagulation therapy, Am J Med, 83, 269, 10.1016/0002-9343(87)90697-8 Wilcox, 1988, Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy, Am J Med, 84, 683, 10.1016/0002-9343(88)90105-2 Wolf, 2007, Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage, Am J Gastroenterol, 102, 290, 10.1111/j.1572-0241.2006.00969.x Culclasure, 1994, The significance of hematuria in the anticoagulated patient, Arch Intern Med, 154, 649, 10.1001/archinte.1994.00420060075008 Schuster, 1987, Clinical significance of hematuria in patients on anticoagulant therapy, J Urol, 137, 923, 10.1016/S0022-5347(17)44295-9 Van Savage, 1995, Anticoagulant associated hematuria: a prospective study, J Urol, 153, 1594, 10.1016/S0022-5347(01)67469-X Garcia, 2009, Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention, Am J Hematol, 84, 579, 10.1002/ajh.21470 Dahri, 2007, The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules, Thromb Haemost, 98, 980, 10.1160/TH07-04-0297 Gage, 2006, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF), Am Heart J, 151, 713, 10.1016/j.ahj.2005.04.017 Wickramasinghe, 1988, Long-term oral anticoagulant therapy in elderly patients, Age Ageing, 17, 388, 10.1093/ageing/17.6.388 Copland, 2001, Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation, Arch Intern Med, 161, 2125, 10.1001/archinte.161.17.2125 Launbjerg, 1991, Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients, J Intern Med, 229, 351, 10.1111/j.1365-2796.1991.tb00358.x The Stroke Prevention in Atrial Fibrillation Investigators, 1996, Bleeding during antithrombotic therapy in patients with atrial fibrillation, Arch Intern Med, 156, 409, 10.1001/archinte.1996.00440040081009 Fihn, 1996, The risk for and severity of bleeding complications in elderly patients treated with warfarin, Ann Intern Med, 124, 970, 10.7326/0003-4819-124-11-199606010-00004 Petitti, 1986, Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage, Am J Med, 81, 255, 10.1016/0002-9343(86)90260-3 McCormick, 1999, Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use, J Thromb Thrombolysis, 7, 157, 10.1023/A:1008884004751 Cheng, 2006, Is age a risk factor for warfarin-related major bleeds in elderly patients with atrial fibrillation?, J Am Geriatr Soc, 54, 1155 Palareti, 2000, Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study, Arch Intern Med, 160, 470, 10.1001/archinte.160.4.470 Fang, 2006, Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study, J Am Geriatr Soc, 54, 1231, 10.1111/j.1532-5415.2006.00828.x Dentali, 2007, Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials, Arch Intern Med, 167, 117, 10.1001/archinte.167.2.117 Flaker, 2006, Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials, Am Heart J, 152, 967, 10.1016/j.ahj.2006.06.024 Rubboli, 2008, Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation, Ann Med, 40, 428, 10.1080/07853890802089786 Hansen, 2010, Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation, Arch Intern Med, 170, 1433, 10.1001/archinternmed.2010.271 Ageno, 2009, Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment, Am J Hematol, 84, 584, 10.1002/ajh.21469 Patel, 2000, Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation, Pharmacotherapy, 20, 1159, 10.1592/phco.20.15.1159.34585 Fondevila, 2001, Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study, Blood Coagul Fibrinolysis, 12, 9, 10.1097/00001721-200101000-00002 Ageno, 2002, Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial, Thromb Haemost, 88, 48 Dentali, 2006, Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms, J Thromb Haemost, 4, 1853, 10.1111/j.1538-7836.2006.01986.x Lubetsky, 2003, Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study, Arch Intern Med, 163, 2469, 10.1001/archinte.163.20.2469 Crowther, 2002, Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial, Ann Intern Med, 137, 251, 10.7326/0003-4819-137-4-200208200-00009 Nee, 1999, Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation, Am J Cardiol, 83, 286, 10.1016/S0002-9149(98)00842-X Raj, 1999, Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione, Arch Intern Med, 159, 2721, 10.1001/archinte.159.22.2721 Riegert-Johnson, 2002, The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review, Ann Allergy Asthma Immunol, 89, 400, 10.1016/S1081-1206(10)62042-X Contreras, 1992, Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force, Transfus Med, 2, 57 Popovsky, 2008, Transfusion-Related Acute Lung Injury: Incidence, Pathogenesis and the Role of Multicomponent Apheresis in Its Prevention, Transfus Med Hemother, 35, 76, 10.1159/000117811 Leissinger, 2008, Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature, Am J Hematol, 83, 137, 10.1002/ajh.21046 Rosovsky, 2008, What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008, Hematology Am Soc Hematol Educ Program, 36, 10.1182/asheducation-2008.1.36 Verhagen, 1954, Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl, Acta Med Scand, 148, 453, 10.1111/j.0954-6820.1954.tb01741.x Weinberg, 1983, Warfarin necrosis of the skin and subcutaneous tissue of the male external genitalia, J Urol, 130, 352, 10.1016/S0022-5347(17)51147-7 Broekmans, 1983, Protein C and the development of skin necrosis during anticoagulant therapy, Thromb Haemost, 49, 251, 10.1055/s-0038-1657378 Zauber, 1986, Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis, Ann Intern Med, 104, 659, 10.7326/0003-4819-104-5-659 Samama, 1984, Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment, Thromb Haemost, 51, 132, 10.1055/s-0038-1661040 Grimaudo, 1989, Necrosis of skin induced by coumarin in a patient deficient in protein S, BMJ, 298, 233, 10.1136/bmj.298.6668.233 Warkentin, 2001, Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis, Ann Intern Med, 135, 589, 10.7326/0003-4819-135-8_Part_1-200110160-00009 Warkentin, 1997, The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia, Ann Intern Med, 127, 804, 10.7326/0003-4819-127-9-199711010-00005 Srinivasan, 2004, Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia, Arch Intern Med, 164, 66, 10.1001/archinte.164.1.66 Raj, 2001, Purple toe syndrome following anticoagulant therapy, Br J Haematol, 114, 740, 10.1046/j.1365-2141.2001.03107.x Talmadge, 2003, Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome, Pharmacotherapy, 23, 674, 10.1592/phco.23.5.674.32200 Hauschka, 1989, Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone, Physiol Rev, 69, 990, 10.1152/physrev.1989.69.3.990 Price, 1988, Role of vitamin K-dependent proteins in bone metabolism, Ann Rev Nutr, 8, 565, 10.1146/annurev.nu.08.070188.003025 Maillard, 1992, Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts, Endocrinology, 130, 1599 Pan, 1985, Sequence of the precursor to rat bone gamma-carboxyglutamic acid protein that accumulates in warfarin-treated osteosarcoma cells, J Biol Chem, 260, 13398, 10.1016/S0021-9258(17)38734-3 Pettifor, 1975, Congenital malformations associated with the administration of oral anticoagulants during pregnancy, J Pediatr, 86, 459, 10.1016/S0022-3476(75)80986-3 Hall, 1980, Maternal and fetal sequelae of anticoagulation during pregnancy, Am J Med, 68, 122, 10.1016/0002-9343(80)90181-3 Barnes, 2005, Reduced bone density in children on long-term warfarin, Pediatr Res, 57, 578, 10.1203/01.PDR.0000155943.07244.04 Danziger, 2008, Vitamin K-dependent proteins, warfarin, and vascular calcification, Clin J Am Soc Nephrol, 3, 1504, 10.2215/CJN.00770208 Lazo-Langner, 2009, Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery, Clin Appl Thromb Hemost, 15, 316, 10.1177/1076029608326166 Diener, 2006, Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies, Cerebrovasc Dis, 21, 279, 10.1159/000091265 Boudes, 2006, The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee, Contemp Clin Trials, 27, 432, 10.1016/j.cct.2006.04.005 Nutescu, 2008, New anticoagulant agents: direct thrombin inhibitors, Cardiol Clin, 26, 169, 10.1016/j.ccl.2007.12.005 Hauel, 2002, Structure-based design of novel potent nonpeptide thrombin inhibitors, J Med Chem, 45, 1757, 10.1021/jm0109513 Wienen, 2007, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, Thromb Haemost, 98, 155 Blech, 2008, The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans, Drug Metab Dispos, 36, 386, 10.1124/dmd.107.019083 Lange, 2003, Ecarin chromogenic assay—a new method for quantitative determination of direct thrombin inhibitors like hirudin, Pathophysiol Haemost Thromb, 33, 184, 10.1159/000081506 Stangier, 2007, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, Br J Clin Pharmacol, 64, 292, 10.1111/j.1365-2125.2007.02899.x Wienen, 2007, Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats, Thromb Haemost, 98, 333 Wienen, 2007, Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis, J Thromb Haemost, 5, 1237, 10.1111/j.1538-7836.2007.02526.x Stangier, 2008, Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects, Clin Pharmacokinet, 47, 47, 10.2165/00003088-200847010-00005 Stangier, 2005, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement, J Clin Pharmacol, 45, 555, 10.1177/0091270005274550 Trocóniz, 2007, Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery, J Clin Pharmacol, 47, 371, 10.1177/0091270006297228 Stangier, 2008, Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate, Clin Pharmacokinet, 47, 285, 10.2165/00003088-200847050-00001 Eriksson, 2004, Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I, J Thromb Haemost, 2, 1573, 10.1111/j.1538-7836.2004.00890.x van Ryn, 2010, Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost, 103, 1116, 10.1160/TH09-11-0758 Stangier, 2010, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study, Clin Pharmacokinet, 49, 259, 10.2165/11318170-000000000-00000 Stangier, 2008, Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment, J Clin Pharmacol, 48, 1411, 10.1177/0091270008324179 Ezekowitz, 2007, Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study), Am J Cardiol, 100, 1419, 10.1016/j.amjcard.2007.06.034 EMEA Mouly, 2009, Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4, Intensive Care Med, 35, 417, 10.1007/s00134-008-1384-1 Stangier, 2009, Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics, Am J Cardiovasc Drugs, 9, 59, 10.1007/BF03256595 Stangier, 2007, Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [abstract], J Thromb Haemost, 5, P-T-677 Marchetti, 2007, Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein), Oncologist, 12, 927, 10.1634/theoncologist.12-8-927 Stangier, 2007, No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [abstract], J Thromb Haemost, 5, P-W-672 Patrono, 2005, Low-dose aspirin for the prevention of atherothrombosis, N Engl J Med, 353, 2373, 10.1056/NEJMra052717 Holmes, 2009, Combining antiplatelet and anticoagulant therapies, J Am Coll Cardiol, 54, 95, 10.1016/j.jacc.2009.03.044 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Eriksson, 2007, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, Lancet, 370, 949, 10.1016/S0140-6736(07)61445-7 Eriksson, 2007, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, J Thromb Haemost, 5, 2178, 10.1111/j.1538-7836.2007.02748.x Ginsberg, 2009, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery, J Arthroplasty, 24, 1, 10.1016/j.arth.2008.01.132 Huo MH, Eriksson B, Dahl OE, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial. Presented at: The European Hematology Association Congress; June 10-13, 2010; Barcelona, Spain Singer, 2008, Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 546S, 10.1378/chest.08-0678 Schulman, 2008, Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 257S, 10.1378/chest.08-0674 Mismetti, 2010, New oral antithrombotics: a need for laboratory monitoring. For, J Thromb Haemost, 8, 621, 10.1111/j.1538-7836.2010.03764.x Bounameaux, 2010, New oral antithrombotics: a need for laboratory monitoring. Against, J Thromb Haemost, 8, 627, 10.1111/j.1538-7836.2010.03759.x Keisu, 2010, Drug-induced liver injury in humans: the case of ximelagatran, Handb Exp Pharmacol, 196, 407, 10.1007/978-3-642-00663-0_13 Agnelli, 2009, Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran, Thromb Res, 123, 488, 10.1016/j.thromres.2008.02.017 Eriksson, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, 2765, 10.1056/NEJMoa0800374 Kakkar, 2008, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, Lancet, 372, 31, 10.1016/S0140-6736(08)60880-6 Lassen, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, N Engl J Med, 358, 2776, 10.1056/NEJMoa076016 Turpie, 2009, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, Lancet, 373, 1673, 10.1016/S0140-6736(09)60734-0 Graff, 2007, Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity, J Clin Pharmacol, 47, 1398, 10.1177/0091270007302952 Perzborn, 2010, Rivaroxaban: a new oral factor Xa inhibitor, Arterioscler Thromb Vasc Biol, 30, 376, 10.1161/ATVBAHA.110.202978 Perzborn, 2005, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor, J Thromb Haemost, 3, 514, 10.1111/j.1538-7836.2005.01166.x Gerotziafas, 2007, In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban, J Thromb Haemost, 5, 886, 10.1111/j.1538-7836.2007.02429.x Lang, 2009, In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans, Drug Metab Dispos, 37, 1046, 10.1124/dmd.108.025551 Samama, 2010, Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor, Thromb Haemost, 103, 815, 10.1160/TH09-03-0176 Kubitza, 2006, Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin, J Clin Pharmacol, 46, 981, 10.1177/0091270006292127 Kubitza, 2005, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, Clin Pharmacol Ther, 78, 412, 10.1016/j.clpt.2005.06.011 Kubitza, 2005, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects, Eur J Clin Pharmacol, 61, 873, 10.1007/s00228-005-0043-5 Mueck, 2007, Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor xa inhibitor—in healthy subjects, Int J Clin Pharmacol Ther, 45, 335, 10.5414/CPP45335 Kubitza, 2008, Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects, Curr Med Res Opin, 24, 2757, 10.1185/03007990802361499 Kubitza, 2007, Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects, J Clin Pharmacol, 47, 218, 10.1177/0091270006296058 Kubitza, 2006, The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor [abstract], Blood, 108, 905, 10.1182/blood.V108.11.905.905 Jiang, 2010, Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban—an oral, direct factor Xa inhibitor—in elderly Chinese subjects, Thromb Haemost, 103, 234, 10.1160/TH09-03-0196 Zhao, 2009, Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects, Br J Clin Pharmacol, 68, 77, 10.1111/j.1365-2125.2009.03390.x Mueck, 2008, Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in patients undergoing major orthopaedic surgery, Clin Pharmacokinet, 47, 203, 10.2165/00003088-200847030-00006 Mueck, 2008, Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement, Thromb Haemost, 100, 453 Bayer Schering Pharma. Xarelto Kubitza, 2008, No interaction between rivaroxaban—a novel, oral, direct factor Xa inhibitor—and atorvastatin [abstract], Pathophysiol Haemost Thromb, 36, A40 Kubitza, 2006, No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin [abstract], J Clin Pharmacol, 46, 11 Kubitza, 2007, Rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—has no clinically relevant interaction with naproxen, Br J Clin Pharmacol, 63, 469, 10.1111/j.1365-2125.2006.02776.x Kubitza, 2006, Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, J Clin Pharmacol, 46, 549, 10.1177/0091270006286904 Tersteegen, 2007, Rivaroxaban—an oral, direct Factor Xa inhibitor— binds rapidly to Factor Xa [abstract], J Thromb Haemost, 5, 651, 10.1111/j.1538-7836.2007.tb03208.x Depasse, 2005, Effect of BAY 59-7939—a novel, oral, direct Factor Xa inhibitor—on clot-bound Factor Xa activity in vitro [abstract], J Thromb Haemost, 3, P1104 Perzborn, 2004, Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct Factor Xa inhibitor [abstract], Pathophysiol Haemost Thromb, 33, 79 Hoppensteadt, 2005, Interaction of BAY 59-7939—a novel, oral, direct Factor Xa inhibitor—with antiplatelet agents: monitoring and therapeutic applications [abstract], J Thromb Haemost, 3, 1717 Perzborn, 2007, Rivaroxaban—an oral, direct Factor Xa inhibitor— inhibits tissue factor-mediated platelet aggregation [abstract], J Thromb Haemost, 5, 642 Smith, 2007, Thromboplastin composition affects the sensitivity of prothrombin time clotting tests to direct Factor Xa inhibitors [abstract], Blood, 110, 928, 10.1182/blood.V110.11.928.928 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 National Institutes of Health Clinical Center, 2008 Turpie, 2011, Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies, Thromb Haemost, 105, 444, 10.1160/TH10-09-0601 Perzborn, 2009, Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats [abstract], J Thromb Haemost, 7, 183 Lu, 2009, Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors [abstract], J Thromb Haemost, 7, OC-TH-107